Innovent reports substantial weight reduction, several metabolic advantages, and a good safety record with a higher dose of 9 mg Mazdutide (IBI362) following a 48-week trial in phase 2 study for obesity.

Merck KGaA, Darmstadt, has formed a strategic partnership with Jiangsu Hengrui Pharmaceuticals Co. Ltd. It holds a global exclusive license to develop, manufacture, and distribute Hengrui’s advanced PARP1 trapping inhibitor HRS-1167.

Coherus BioSciences, Inc. along with Shanghai Junshi Biosciences Co., Ltd. revealed that the FDA has given its approval for LOQTORZI™ (toripalimab-tpzi) to be used with cisplatin and gemcitabine.

Kymera Therapeutics discloses initiation of Phase 2 trial with KT-474 (SAR444656), a novel IRAK4 degrader, being administered to its first Hidradenitis Suppurativa patient.

Otsuka Pharmaceutical, including its U.S. division, reported promising results from two Phase 3 trials evaluating centanafadine's efficacy and safety in managing ADHD in children and teens.

ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.

TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.

Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.

Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.

The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.

Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).

Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.